MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
Contineum Therapeutics, Inc. (CTNM), formerly, Pipeline Therapeutics
Organization & Developments: Contineum
Parents
Contineum Therapeutics, Inc. (CTNM), formerly, Pipeline Therapeutics
Children
*Contineum is focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need.
*The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to the nervous system.
2023: Pipeline Therapeutics Changes Name to Contineum Therapeutics to Reflect Expanded Focus on NI&I Therapeutic Indications (Neuroscience, Inflammation and Immunology)
2024: With MS & Fibrosis Trials Planned, J&J-Partnered Contineum Now Preps for IPO
Jumps
Finance & Acquisitions: Contineum
Key People: Contineum